31 – 40 of 91
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2010
-
Mark
Lu-177-[DOTA0,Tyr3] Octreotate Therapy in Patients With Disseminated Neuroendocrine Tumors: Analysis of Dosimetry With Impact on Future Therapeutic Strategy
(
- Contribution to journal › Article
-
Mark
Vandetanib In Locally Advanced Or Metastatic Differentiated Thyroid Cancer (Papillary Or Follicular; Dtc): A Randomized, Double-Blind Phase Ii Trial
2010) 35th European-Society-for-Medical-Oncology (ESMO) Congress In Annals of Oncology 21. p.315-315(
- Contribution to journal › Published meeting abstract
- 2009
-
Mark
Development and evaluation of a pharmacokinetic model for prediction of radioimmunotherapy based on pretherapy data.
(
- Contribution to journal › Article
-
Mark
Peptide Receptor Radionuclide Therapy (PRRT) Using 177Lu-DOTATATE: Early Clinical and Dosimetric Results
2009) 6th Annual Conference of the European-Neuroendocrine-Tumor-Society In Neuroendocrinology 90(1). p.44-44(
- Contribution to journal › Published meeting abstract
-
Mark
High-dose iodine-131-metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed/refractory neuroblastoma.
(
- Contribution to journal › Article
- 2008
-
Mark
Evaluation of toxicity-reducing potential of ECAT in combination with drug-conjugated mAb BR96
2008) Twelfth Conference on Cancer Therapy with Antibodies and Immunoconjugates In Cancer Biotherapy and Radiopharmaceuticals 23(4). p.520-520(
- Contribution to journal › Published meeting abstract
-
Mark
Consequences of Inadvertent Radioiodine Treatment of Graves' Disease and Thyroid Cancer in Undiagnosed Pregnancy. Can We Rely on Routine Pregnancy Testing?
(
- Contribution to journal › Article
-
Mark
Peptide receptor radionuclide therapy (PRRT) using Lu-177-Dotatate: Early clinical and dosimetric results
2008) Twelfth Conference on Cancer Therapy with Antibodies and Immunoconjugates In Cancer Biotherapy and Radiopharmaceuticals 23(4). p.524-525(
- Contribution to journal › Published meeting abstract
-
Mark
High dose radioimmunotherapy combined with extracorporeal depletion in syngeneic rat tumor model. Evaluation of toxicity, therapeutic effect, and tumor model
2008) Twelfth Conference on Cancer Therapy with Antibodies and Immunoconjugates In Cancer Biotherapy and Radiopharmaceuticals 23(4). p.517-517(
- Contribution to journal › Published meeting abstract
-
Mark
Guidelines for radioiodine therapy of differentiated thyroid cancer
(
- Contribution to journal › Scientific review